Insulet
PODD
717 hedge funds and large institutions have $18.7B invested in Insulet in 2025 Q1 according to their latest regulatory filings, with 94 funds opening new positions, 298 increasing their positions, 226 reducing their positions, and 48 closing their positions.
96% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 48
32% more repeat investments, than reductions
Existing positions increased: 298 | Existing positions reduced: 226
5% more funds holding
Funds holding: 682 → 717 (+35)
1% more capital invested
Capital invested by funds: $18.4B → $18.7B (+$236M)
0.42% more ownership
Funds ownership: 100.53% → 100.96% (+0.42%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
32% less call options, than puts
Call options by funds: $103M | Put options by funds: $150M
Top Buyers
Top Sellers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$371M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$174M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$158M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
-$89.7M |
| 5 |
PA
Perceptive Advisors
New York
|
-$43.5M |
PODD Hedge Fund Activity: Q1 2025 in Review
717 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Insulet (PODD) for Q1 2025, worth a combined $18.7B — up 1.3% from $18.4B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new PODD positions and 48 closed out — a net gain of 46 holders — while 298 added to existing stakes and 226 trimmed.
The largest buyer was Macquarie Group, adding an estimated $109M. The largest seller was Capital Research Global Investors, cutting an estimated $371M.
- 717 institutional investors held Insulet (PODD) as of Q1 2025, up from 682 in Q4 2024.
- Funds reported $18.7B of Insulet stock for Q1 2025, up 1.3% quarter-over-quarter.
- 94 funds opened new Insulet positions in Q1 2025 and 48 closed out, a net change of +46 holders.
- The largest Insulet buyer in Q1 2025 was Macquarie Group, an estimated $109M added.
- The largest Insulet seller in Q1 2025 was Capital Research Global Investors, an estimated $371M sold.
Based on aggregated 13F filings for Q1 2025.